Step 1 topics → General Pathology → Tumor Markers

Tumor Markers

USMLE Step 1 trap: Confuses PSA's role as a monitoring marker with its limited utility as a diagnostic screening test. PSA is best used for monitoring treatment response and recurrence in known prostate cancer; it lacks sufficient specificity for definitive screening or diagnosis.

Tumor markers are molecules — proteins, hormones, enzymes — detectable in blood or tissue that correlate with certain malignancies. On USMLE Step 1, you're not just memorizing which marker goes with which cancer. The exam tests whether you know *how* to use them clinically: when to order them, what they actually tell you, and what they don't. Expect vignettes where a patient has a known cancer and you're asked what to follow over time, or where you're handed a germ cell tumor with AFP/hCG levels and need to classify the histology.

The trickiest part of this topic is the distinction between screening, diagnosis, and monitoring. Most students collapse these into one category and get burned. PSA is the classic trap — it feels like a diagnostic test because it's so commonly ordered, but Step 1 specifically rewards students who know it lacks the specificity to confirm prostate cancer. Similarly, CEA and CA-125 are monitoring tools, not diagnostic ones. Elevated CEA in a post-colectomy patient tells you something; elevated CEA in a healthy person tells you almost nothing actionable.

The germ cell tumor panel (AFP + hCG) is a separate high-yield cluster. USMLE Step 1 loves this because it ties serology directly to histology — knowing that a pure seminoma does NOT elevate AFP, while a yolk sac tumor (endodermal sinus tumor) does, lets you answer classification questions even without pathology images. AFP elevation also bleeds into HCC and pregnancy, which is where students get tripped up. Get comfortable with the idea that no single marker is pathognomonic — they're all contextual.

From real student decks
70%have cards covering this topic
46%have mature cards

Common misconceptions

Common mistake
Wrong: PSA is a reliable screening test that confirms prostate cancer diagnosis.
Right: PSA is best used for monitoring treatment response and recurrence in known prostate cancer; it lacks sufficient specificity for definitive screening or diagnosis.
PSA is prostate-specific, not prostate-cancer-specific — it rises in benign prostatic hyperplasia, prostatitis, and even after prostate manipulation, which tanks its specificity for screening. Using PSA to diagnose prostate cancer would generate enormous false positives. Where PSA shines is post-treatment: if a patient had prostatectomy and PSA starts rising again, that's a sensitive signal for recurrence. Know the difference between 'specific to the organ' and 'specific to the cancer.'
Common mistake
Wrong: Elevated AFP always indicates hepatocellular carcinoma.
Right: AFP is elevated in hepatocellular carcinoma, yolk sac tumors (endodermal sinus tumors), and physiologically in pregnancy; it is not specific to HCC.
AFP is a fetal protein produced by the yolk sac and fetal liver, so any tissue recapitulating those origins can re-elevate it. In adults, HCC is the most common malignant cause, but yolk sac tumors (also called endodermal sinus tumors) are the key germ cell tumor that elevates AFP — this is critical for classifying testicular tumors. AFP is also physiologically elevated in pregnancy, which the exam sometimes uses to distract you. Elevated AFP is a clue, never a confirmed diagnosis of HCC.
Common mistake
Wrong: CEA elevation is specific for colorectal cancer.
Right: CEA is a nonspecific marker elevated in colorectal, pancreatic, gastric, and breast cancers, as well as in smokers; it is used for monitoring, not diagnosis.
CEA (carcinoembryonic antigen) is an oncofetal antigen with essentially no specificity for any single cancer — it can be elevated in colorectal, pancreatic, gastric, breast, and lung cancers, and even in smokers without cancer. Ordering CEA to 'diagnose' colorectal cancer in a new patient is inappropriate. Its real value is as a baseline before surgery and a trend marker after: a rising CEA in a post-colectomy patient is a red flag for recurrence and warrants workup. Always frame CEA as a monitoring tool.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the classic marker-to-malignancy pairings: which markers go with which cancers, including PSA (prostate), CEA (colorectal/gastric/pancreatic/breast), AFP (HCC and yolk sac tumor), hCG (choriocarcinoma and mixed germ cell tumors), CA-125 (ovarian), CA 19-9 (pancreatic), LDH (lymphoma/testicular), S-100 (melanoma and neural-crest tumors), chromogranin (neuroendocrine tumors), and calcitonin (medullary thyroid carcinoma).
  2. Understand when tumor markers are clinically appropriate: they are used primarily to monitor treatment response and detect recurrence in known malignancies, not to screen asymptomatic populations or confirm a diagnosis.
  3. Use AFP and hCG together to classify testicular germ cell tumors: pure seminoma elevates hCG mildly but never AFP; elevated AFP points to a nonseminomatous component (yolk sac tumor); this distinction has direct management implications.

Can you avoid these mistakes?

A 65-year-old man undergoes radical prostatectomy for prostate cancer. Six months later his PSA, which had been undetectable, rises to 0.4 ng/mL. What does this indicate, and why is PSA the right marker to follow here?
A 24-year-old man has a testicular mass. Workup shows AFP markedly elevated and hCG mildly elevated. Is this consistent with pure seminoma? What histologic component does the AFP elevation implicate?
A physician orders CEA on a 50-year-old asymptomatic patient during a routine checkup. The result comes back mildly elevated. A colleague says this confirms early colorectal cancer. What is wrong with this reasoning?
Match each marker to its best-fit clinical scenario: (A) Calcitonin, (B) Chromogranin, (C) CA-125, (D) S-100 — with: (1) monitoring recurrence of ovarian cancer after debulking, (2) workup of a posterior neck mass with hypercalcemia, (3) staging of a suspected carcinoid tumor, (4) evaluation of a pigmented skin lesion with lymphadenopathy.

Related topics

Benign vs Malignant Neoplasia Reversible vs Irreversible Cell Injury Types of Necrosis Apoptosis (Intrinsic and Extrinsic Pathways) Cell Adaptations (Atrophy, Hypertrophy, Hyperplasia, Metaplasia, Dysplasia)

See how your Anki deck covers this topic.

Upload your deck for a free audit →